Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCA-N Solution
- Development stage
- Phase 3
- Lead developer
- Zhongnan Hospital of Wuhan University
- Administration
- Parenteral
01
Overview
HCA-N Solution is a modified version of the classic Hypertonic Citrate Adenine (HC-A) organ preservation solution. It is designed for the static cold storage and preservation of donor kidneys during renal transplantation. The solution is formulated to counteract graft edema, reduce oxidative stress, and maintain cellular energy levels during cold ischemia. By optimizing the electrolyte and osmotic balance, HCA-N aims to minimize ischemia-reperfusion injury, reduce the incidence of delayed graft function (DGF), and accelerate the recovery of early renal function post-transplantation compared to standard preservation solutions like Histidine-Tryptophan-Ketoglutarate (HTK).
- Other names
- HCA-N
Beyond the preview
Go deeper on HCA-N Solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCA-N Solution.